Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Decoding The Immune System To Speed Vaccine/Immunotherapy R&D

Executive Summary

The Human Vaccines Project, a consortium of biopharmaceutical companies, academic institutions and nonprofit product developers, is aiming to conduct numerous small, focused trials in an effort to decode the human immune system to improve the way vaccines and immunotherapies are developed.

You may also be interested in...



Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds

Regeneron Pharmaceuticals Inc. executives emphasized the blockbuster potential of product candidates in the company's late-stage research and development pipeline on Aug. 4, while noting that the top-selling biologic Eylea (aflibercept) is facing increased reimbursement and competitive pressures.

US Capitol Capsule: The vaccine pursuit: Not for the faint of heart

With the successes in the past few weeks of vaccines for Ebola and malaria – both being described as game-changers for the diseases they are intended to prevent – the industry and researchers have much to celebrate.

Consortia advice: Be focused, yet flexible

When the Human Genome Project officially got underway in 1990, the notion of consortium-based biomedical research was scary to many scientists, said Dr Eric Green, director of the National Human Genome Research Institute at the National Institutes of Health (NIH).

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC065386

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel